An observational study in HFrEF - Heart Failure With Reduced Ejection Fraction and Guideline Adherence, sponsored by Jasper Brugts MD PhD. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Jasper Brugts MD PhD · Observational
The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4 pillars of guideline directed medical therapy (GDMT) in HFrEF patients will help to further improve the implementation of GDMT.
Data will be used from the national HF registry in the Netherlands. Two groups will be studied, one where the HCP receives the mirror information on GDMT and one where both the patient and the HCP receive the mirror information on GDMT. GDMT or the 4 pillars treatment is standard of care as recommended by the ESC HF guidelines, indicated for all HFrEF patients. The project is a quality of care registry and health care evaluation to optimize adherence to the HF guidelines.
The IMPLEMENT HF is a sequel study to the TITRATE HF study that has shown that the level of GDMT prescription in de novo HFrEF can be further improved. The investigators hypothesize that mirror information about actual levels of GDMT helps the physician and patient optimize GDMT as recommended in the guideline. The IMPLEMENT is a registry based study in 1500 with de novo HFrEF patients, in which mirror information on GDMT (4 pillars) prescription levels will be shown to the treating physician. In a second group (50%) both the physician and patient will receive the mirror information on the prescription of GDMT. For diversity, the investigators aim to include 50% elderly and 50% women in to the registry. The primary endpoint is the prescription level of GDMT. Secondary endpoints are the dosing levels of GDMT (% target dose) and incident clinical events.
This is the only study on the registry with Jasper Brugts MD PhD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with de novo / newly diagnosed heart failure with reduced ejection fraction
Exclusion Criteria:
At enrollment the patient has heart failure with reduction ejection fraction with an established EF below 40%.
Guideline recommended drug therapy for HFrEF with mirror information to HCP
Guideline recommended drug therapy for HFrEF with mirror information to HCP and patient.
The prescription level (%) of GDMT / 4 pillars in de novo HFrEF patients.
The prescription level (%) of GDMT / 4 pillars in patients with de novo HFrEF at specific time moments durign 1 year (6 weeks, 3 Months , 6 Months, 12 Months)
Time frame: 1 year of follow-up
The % of target dose of GDMT prescribed in de novo HFrEF patients
The dosing level of a GDMT drug class as % of the guideline recommended dose during 1 year of follow-up.
Time frame: 1 year (evaluated at time moments 6 weeks, 3 Months, 6 Months, 12 Months).
Incident events
The incidence of all-cause mortality and HF hospitalisations during 12 months of follow-up (and the individual components of the composite outcome).
Time frame: 1 year of follow-up (12 months)
GDMT adherence in subgroups of age (elderly) and sex (men/women)
GDMT adherence in subgroups of age (elderly) and sex (men/women)
Time frame: 12 months
No study locations are listed for this record.
Plan to share: Undecided — The project is part of the NHR HF registry and follow the protocols and rules of the NHR on IPD accordingly (including GDPR/AVG), when applicable.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.